COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Mount Qomolangma's foreign tourist number doubles in 2024
- Yuyuan Garden lights up with Year of the Snake lantern installations
- New dendrobium orchid species found in Sichuan
- People welcome the New Year across China
- China's railway trips expected to hit 11.5 million on New Year's Day
- Beijing: where ancient traditions meet modern marvels
